» Articles » PMID: 31004046

Postvaccination Febrile Seizure Severity and Outcome

Overview
Journal Pediatrics
Specialty Pediatrics
Date 2019 Apr 21
PMID 31004046
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Febrile seizures (FSs) are a common pediatric condition caused by a sudden rise in temperature, affecting 3% to 5% of children aged ≤6 years. Although vaccination can cause FSs, little is known on whether FSs occurring in the time soon after vaccination (vaccine-proximate febrile seizures [VP-FSs] differ clinically from non-vaccine-proximate febrile seizures [NVP-FSs]). We compared the clinical profile and outcomes of VP-FS to NVP-FS.

Methods: Prospective cohort study of children aged ≤6 years presenting with their first FS at 1 of 5 Australian pediatric hospitals between May 2013 and June 2014. Clinical features, management, and outcomes were compared between VP-FS and NVP-FS.

Results: Of 1022 first FS cases (median age 19.8 months; interquartile range 13.6-27.6), 67 (6%) were VP-FSs. When comparing VP-FS to NVP-FS, there was no increased risk of prolonged (>1 day) hospitalization (odds ratio [OR] 1.61; 95% confidence interval [95% CI] 0.84-3.10), ICU admission (OR 0.72; 95% CI 0.10-5.48), seizure duration >15 minutes (OR 1.47; 95% CI 0.73-2.98), repeat FS within 24 hours (OR 0.80; 95% CI 0.34-1.89), or requirement for antiepileptic treatment on discharge (OR 1.81; 95% CI 0.41-8.02). VP-FS patients with a laboratory-confirmed infection (12%) were more likely to have a prolonged admission compared with those without.

Conclusions: VP-FS accounted for a small proportion of all FS hospital presentations. There was no difference in outcomes of VP-FS compared with NVP-FS. This is reassuring data for clinicians and parents of children who experience FS after vaccination and can help guide decisions on revaccination.

Citing Articles

SMS-Based Active Surveillance of Adverse Events following Immunization in Children: The VigiVax Study.

Gonella L, Moretti F, Capuano A, De Sarro C, Ferrara L, Geninatti E Vaccines (Basel). 2024; 12(9).

PMID: 39340106 PMC: 11435886. DOI: 10.3390/vaccines12091076.


Active Vaccine Safety Surveillance: Global Trends and Challenges in China.

Liu Z, Meng R, Yang Y, Li K, Yin Z, Ren J Health Data Sci. 2024; 2021:9851067.

PMID: 38487501 PMC: 10880162. DOI: 10.34133/2021/9851067.


The baseline risk of multiple febrile seizures in the same febrile illness: a meta-analysis.

Henry C, Cockburn C, Simpson M, Budd S, Wang C, Dinov D Eur J Pediatr. 2022; 181(6):2201-2213.

PMID: 35292852 PMC: 9468602. DOI: 10.1007/s00431-022-04431-w.


Study of Febrile Seizure among Hospitalized Children of a Tertiary Centre of Nepal: A Descriptive Cross-sectional Study.

Pokhrel R, Bhurtel R, Karmacharya Malla K, Shah L JNMA J Nepal Med Assoc. 2021; 59(238):526-530.

PMID: 34508412 PMC: 8369564. DOI: 10.31729/jnma.6092.


From program suspension to the pandemic: A qualitative examination of Australia's vaccine pharmacovigilance system over 10 years.

Phillips A, Carlson S, Danchin M, Beard F, Macartney K Vaccine. 2021; 39(40):5968-5981.

PMID: 34376308 PMC: 8445694. DOI: 10.1016/j.vaccine.2021.07.059.